Close menu




October 30th, 2024 | 07:45 CET

Nyxoah, Bayer and Palantir - The billion-dollar precision medicine market: Why investors are now taking notice

  • Biotechnology
  • Biotech
  • medtech
  • Software
  • Pharma
Photo credits: pixabay.com

Precision medicine is revolutionizing global healthcare: Experts predict that this future market will reach over USD 175 billion by 2028, driven by the growing demand for individualized treatment methods. Three companies stand out in particular: Belgian medical technology company Nyxoah is developing a mask-free therapy for the 936 million people worldwide with sleep apnea with its Genio system, while Bayer AG is revolutionizing fertility treatment through real-time hormone monitoring through its partnership with Impli. With its foundry platform, technology leader Palantir enables pharmaceutical giant Sanofi to analyze the health data of over 300 million patients. These patient-centered innovations not only promise better treatment outcomes for millions of people but also present investors access to one of the most dynamic growth markets in the healthcare sector.

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: NYXOAH SA | BE0974358906 , BAYER AG NA O.N. | DE000BAY0017 , PALANTIR TECHNOLOGIES INC | US69608A1088

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    MEDTECH COMPANY NYXOAH EXPANDS INTO A BILLION-DOLLAR MARKET: INNOVATIVE NEUROSTIMULATION TECHNOLOGY FOR PATIENTS WITH OBSTRUCTIVE SLEEP APNEA

    The market for obstructive sleep apnea (OSA) is huge: 936 million people worldwide between the ages of 30 and 69 are affected, 425 million of whom require treatment for moderate to severe OSA. The health consequences are serious: the risk of heart attack increases by 30%, the risk of stroke rises sevenfold, and life expectancy decreases by an average of 10 years.

    The current standard therapy using a CPAP mask (continuous positive airway pressure) is a considerable burden for many patients and their partners. The Belgian medical technology company Nyxoah offers a promising alternative with its innovative Genio® system.

    The CE-certified system works with a small stimulator under the chin that is connected to the lingual nerve. A chip attached at night activates the system, which uses gentle electrical impulses to move the tongue forward and keep the airways clear. Particularly interesting for investors: the system is already in use in Germany, among others at the Helios Clinics. Additionally, the company awaits FDA approval until the end of this year and plans to begin commercialization of Genio® in the USA in the first quarter of 2025.

    Investors have the opportunity to invest in a patient-centered medical technology company that is addressing a rapidly growing billion-dollar market. The share is currently trading at EUR 8.88. Nyxoah, whose name is derived from the Greek words for night (referring to the period when OSA occurs) and owl (a symbol of wisdom), has been listed on Euronext in Brussels since 2020 and at Nasdaq in the US since 2021.

    The timing for this innovation appears optimal as the number of people affected is increasing worldwide and acceptance of traditional CPAP therapy is limited. Doctors see the development as a potential turning point in the treatment of this widespread sleep-related breathing disorder.

    Bayer is revolutionizing fertility treatment: New precision health partnership for real-time hormone monitoring

    Women's health has long been a profitable market for Bayer AG, particularly in reproductive and hormonal health. While Bayer generates significant revenue from hormonal contraceptive products, many women and couples dream of having a child. Yet, for some, conception proves challenging. Before considering surrogacy, many couples turn to fertility or IVF clinics. In this process, women undergo hormone treatments to stimulate the body's own egg production. Eggs are retrieved, artificially fertilized, and implanted back into the uterus (in vitro).

    The procedure is very stressful for women and couples. In addition to the psychological pressure that it "must finally work," the chance of successful artificial insemination decreases the more external hormonal stimulation is used.

    The pharmaceutical division of Bayer AG has now announced a strategic partnership with the deep-tech start-up Impli. The focus of the collaboration is the development of the world's first system for real-time hormone monitoring, which is expected to set new standards, particularly in fertility treatment.

    The device is placed under the skin with a small procedure, as is the case with Nyxoah. Impli can then determine the time frame of the hormonal deadline for the IVF procedure more precisely. This innovative technology is implanted under the skin of the woman undergoing IVF treatment and enables continuous measurement of the relevant hormones throughout the entire IVF process. This not only allows for more precise control of fertility treatments but also makes them safer.

    The global IVF market is showing impressive growth: from USD 17.13 billion in 2023, it will grow to USD 27.67 billion by 2028, according to The Business Research Company, with a compound annual growth rate of 9.7%. The main driver is the increasing rate of infertility. Europe dominates with a market share of 44.8%.

    The immediate availability of hormone levels allows treating physicians to individually adjust and optimize therapy. This leads to better success rates and makes the treatment more accessible for couples wanting children. Real-time monitoring thus marks a significant advance in reproductive medicine.

    The new measurement system is intended not only for use in reproductive medicine but also to provide insights into the relationship between hormones, stress, sleep and general health. The market launch is planned for next year.

    Palantir shows strength: Technology leader impresses with solid financial structure and growth in the healthcare sector

    Palantir differs from many other technology companies in its very cautious financial policy: while its competitors are often heavily in debt, Palantir operates almost debt-free. This makes the Company particularly stable. In the second quarter of 2024, Palantir also increased its earnings per share by 20% to USD 0.06.

    The Company's innovative strength is particularly evident in the healthcare sector. A prime example is its collaboration with the pharmaceutical company Sanofi, which has achieved a significant breakthrough in health data analysis using Palantir's Foundry platform. The award-winning platform integrates medical data from over 300 million patients. It processes billions of data points from a wide range of sources, from traditional medical records and patient registries to data from wearables.

    The real breakthrough lies in the ability to study the efficacy and safety of drugs under real-world conditions. This enables significantly more precise and patient-oriented treatment. The platform allows researchers with different levels of technical expertise to perform complex analyses using state-of-the-art statistical methods and machine learning. The combination of financial stability and technological innovation makes the Company an interesting candidate for long-term investors.


    With the Genio® system, Nyxoah is addressing an enormous global healthcare market: of the 936 million people worldwide with obstructive sleep apnea, 425 million require urgent treatment. The CE certification, the successful market launch in Germany, and, above all, the upcoming market launch in the USA offer significant growth potential. Given the high number of unreported cases (around 80% of those affected are still undiagnosed) and the low acceptance of conventional CPAP therapy, the current share price of EUR 8.88 could represent an attractive entry point for investors. The collaboration between Bayer and Impli marks a turning point in fertility treatment. The innovative real-time hormone system not only promises better success rates for IVF treatments but also opens up new possibilities in the broader field of hormone health. For Bayer, this means a strengthening of its position in the lucrative women's health market. Palantir impresses with an exceptionally solid financial structure and continuous growth. The successful implementation of the Foundry platform at Sanofi demonstrates the enormous potential in the healthcare sector. The combination of financial stability, technological leadership, and growing market share makes Palantir a promising investment for long-term investors.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Armin Schulz on November 12th, 2024 | 07:00 CET

    Bayer, BioNxt Solutions, Novo Nordisk – Opportunities in the healthcare industry

    • Biotechnology
    • Biotech
    • Pharma

    In a market characterized by technological breakthroughs and the growing demand for innovative therapies, companies such as Bayer, BioNxt Solutions and Novo Nordisk offer exciting investment opportunities. While Bayer, a global pharmaceutical giant with a broad product portfolio, promises stability and long-term growth, BioNxt Solutions relies on highly specialized biotechnological innovations with disruptive potential. Novo Nordisk, a leading player in diabetes and metabolic disorders, is benefiting from the growing demand for solutions for chronic diseases. For investors looking to capitalize on trends in the healthcare industry, these three companies could make all the difference.

    Read

    Commented by Fabian Lorenz on November 7th, 2024 | 07:15 CET

    TUI, Evotec, BioNxt Solutions: Short squeeze potential, Price drops, and Momentum

    • Biotechnology
    • Biotech
    • Travel

    BioNxt Solutions' stock has gained 50% since the end of August. The chances are good that the momentum will continue for the biotech company. The stock would need to more than double to reach its January level. The industry environment is favorable, the news flow is positive, and takeover speculation exists. Takeover speculation is perhaps the only positive factor for Evotec's share at the moment. The operational development is certainly not. Yesterday, the Company reported a significant drop in earnings. Is there any improvement in sight? Operationally, TUI has been doing well for quite some time. With a jump in the share price, the stock is now setting its sights on the resistance at EUR 8. Could there even be a short squeeze? Analysts may also shift to the bull camp.

    Read

    Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET

    Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors

    • Biotechnology
    • Biotech
    • Pharma

    Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?

    Read